文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

PLT012，一种人源化抗CD36抗体，对释放针对肝癌和肝转移的抗肿瘤免疫有效。

PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis.

作者信息

Tzeng Sheue-Fen, Yu Yi-Ru, Park Jaeoh, von Renesse Janusz, Hsiao Huey-Wen, Hsu Chen-Hsuan, Garnica Josep, Chen Jintian, Chiu Lu-Ting, Santol Jonas, Chen Tse-Yu, Chung Pei-Han, Kandalaft Lana E, Starlinger Patrick, Hsieh Rodney Cheng-En, Yu Ming-Chin, Hsiao Pei-Wen, Carmona Santiago J, Chen Hung-Kai, Meng Zhen, Lin Yun-Han, Zhou Jingying, Tsai Chin-Hsien, Ho Ping-Chih

机构信息

Tumor Immune Analysis Core, Office of Research & Development, Taipei Medical University, Taipei, Taiwan.

Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.

出版信息

Cancer Discov. 2025 Apr 28:OF1-OF21. doi: 10.1158/2159-8290.CD-24-1409.

DOI:10.1158/2159-8290.CD-24-1409
PMID:40294022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7617665/
Abstract

Despite the success of cancer immunotherapies, like immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors. PLT012 rejuvenates antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with potential to influence future HCC immunotherapy.

摘要

尽管癌症免疫疗法取得了成功，如免疫检查点抑制剂，但由于肿瘤中的代谢限制，许多患者仍未能表现出显著反应。PLT012通过靶向代谢途径来重塑肝癌和肝转移的免疫格局，从而恢复抗肿瘤免疫力，有可能影响未来的肝癌免疫治疗。

相似文献

[1]
PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis.

Cancer Discov. 2025-4-28

[2]
Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.

J Exp Clin Cancer Res. 2025-7-15

[3]
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.

Immunotherapy. 2025-4

[4]
Serotonin receptor 5-HT as a potential target for HCC immunotherapy.

J Immunother Cancer. 2025-6-23

[5]
Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy.

Front Immunol. 2025-6-20

[6]
Targeting USP47 enhances immunotherapy in hepatocellular carcinoma by destabilizing PD-L1.

Int Immunopharmacol. 2025-8-28

[7]
Nanoliposomal PD-1 antagonist target tumor-draining lymph nodes to revitalize T cells and improve anti-tumor effect in hepatocellular carcinoma.

J Nanobiotechnology. 2025-7-30

[8]
CD36 Promotes Iron Accumulation and Dysfunction in CD8+ T Cells via the p38-CEBPB-TfR1 Axis in Early-stage Hepatocellular Carcinoma.

Clin Mol Hepatol. 2025-3-4

[9]
Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.

Cancer Lett. 2021-8-10

[10]
Ganoderic acid A regulates CSF1R to reprogram tumor-associated macrophages for immune therapy of hepatocellular carcinoma.

Int Immunopharmacol. 2025-8-28

引用本文的文献

[1]
Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer.

Sci Rep. 2025-8-6

本文引用的文献

[1]
PPARβ/δ-orchestrated metabolic reprogramming supports the formation and maintenance of memory CD8 T cells.

Sci Immunol. 2024-8-23

[2]
Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank.

Nat Commun. 2024-5-2

[3]
Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk.

Nat Commun. 2024-4-2

[4]
Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma.

EBioMedicine. 2024-3

[5]
Fatty acid metabolism of immune cells: a new target of tumour immunotherapy.

Cell Death Discov. 2024-1-20

[6]
Immunosurveillance encounters cancer metabolism.

EMBO Rep. 2024-2

[7]
CD36 maintains lipid homeostasis via selective uptake of monounsaturated fatty acids during matrix detachment and tumor progression.

Cell Metab. 2023-11-7

[8]
Regulatory circuits of mitophagy restrict distinct modes of cell death during memory CD8 T cell formation.

Sci Immunol. 2023-9-29

[9]
Extending support for mouse data in the Molecular Signatures Database (MSigDB).

Nat Methods. 2023-11

[10]
Identification of pre-diagnostic lipid sets associated with liver cancer risk using untargeted lipidomics and chemical set analysis: A nested case-control study within the ATBC cohort.

Int J Cancer. 2024-2-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索